Clinical utility, safety, and tolerability of ezogabine (retigabine) in the treatment of epilepsy

References

• HesdorfferDCLogroscinoGBennEKKatriNCascinoGHauserWAEstimating risk for developing epilepsy: a population-based study in Rochester, MinnesotaNeurology2011761232721205691
   PubMed Web of Science ®Google Scholar
• NadkarniJJainADwivediRQuality of life in children with epilepsyAnn Indian Acad Neurol201114427928222346017
   PubMed Web of Science ®Google Scholar
• BacaCBVickreyBGVassarSDBergATSeizure recency and quality of life in adolescents with childhood-onset epilepsyEpilepsy Behav2012231475122134098
   PubMed Web of Science ®Google Scholar
• SillanpääMShinnarSLong-term mortality in childhood-onset epilepsyN Engl J Med2010363262522252921175314
   PubMed Web of Science ®Google Scholar
• ForsgrenLHauserWAOlafssonESanderJWSilanpääMTomsonTMortality of epilepsy in developed countries: a reviewEpilepsia200546Suppl 11182716393174
   PubMed Web of Science ®Google Scholar
• StrineTWKobauRChapmanDPThurmanDJPricePBalluzLSPsychological distress, comorbidities, and health behaviors among US adults with seizures: results from the 2002 National Health Interview SurveyEpilepsia20054671133113916026567
   PubMed Web of Science ®Google Scholar
• ElgerCESchmidtDModern management of epilepsy: a practical approachEpilepsy Behav200812450153918314396
   PubMed Web of Science ®Google Scholar
• KwanPBrodieMJEarly identification of refractory epilepsyN Engl J Med2000342531431910660394
   PubMed Web of Science ®Google Scholar
• RheimsSRyvlinPRetigabine for partial onset seizuresExpert Rev Neurother201212550951722550979
   PubMed Web of Science ®Google Scholar
• LargeCHSokaiDMNehligAThe spectrum of anticonvulsant efficacy of retigabine (ezogabine) in animal models: implications for clinical useEpilepsia201253342543622221318
   PubMed Web of Science ®Google Scholar
• RejdakKLuszczkiJJBłaszczykBChwedorowiczRCzuczwarSJClinical utility of adjunctive retigabine in partial onset seizure in adultsTher Clin Risk Manag2012871422298949
   PubMed Web of Science ®Google Scholar
• StafstromCEGripponSKirkpatrickPEzogabine (retigabine)Nat Rev Drug Discov2011101072973021959281
   PubMed Web of Science ®Google Scholar
• WeisenbergJLWongMProfile of ezogabine (retigabine) and its potential as an adjunctive treatment for patients with partial-onset seizuresNeuropsychiatr Dis Treat2011740941421792307
   PubMed Web of Science ®Google Scholar
• RostockAToberCRundfeldtCD-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizuresEpilepsy Res19962332112238739124
   PubMed Web of Science ®Google Scholar
• WickendenADYuWZouAJeglaTWagonerPKRetigabine, a novel anticonvulsant, enhances activation of KCNQ2/Q3 potassium channelsMol Pharmacol200058359160010953053
   PubMed Web of Science ®Google Scholar
• MainMJCryanJEDupereJRCoxBClareJJBurbidgeSAModulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabineMol Pharmacol200058225326210908292
   PubMed Web of Science ®Google Scholar
• WuttkeTVSeebohmGBailSMaljevicSLercheHThe new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gateMol Pharmacol20056741009101715662042
   PubMed Web of Science ®Google Scholar
• RundfeldtCNetzerRThe novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunitsNeurosci Lett2000282102737610713399
   PubMed Web of Science ®Google Scholar
• TatulianLDelmasPAbogadieFCBrownDAActivation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabineJ Neurosci200121155535554511466425
   PubMed Web of Science ®Google Scholar
• JentschTJNeuronal KCNQ potassium channels: physiology and role in diseaseNat Rev Neurosci200011213011252765
   PubMed Web of Science ®Google Scholar
• KharkovetsTDedekKMaierHMice with altered KCNQ4 K+ channels implicate sensory outer hair cells in human progressive deafnessEMBO J200625364265216437162
   PubMed Web of Science ®Google Scholar
• GreenwoodIAOhyaSNew tricks for old dogs: KCNQ expression and role in smooth muscleBr J Pharmacol200915681196120319751313
   PubMed Web of Science ®Google Scholar
• JeppsTAGreenwoodIAMoffattJDSandersKMOhyaSMolecular and functional characterization of Kv7 K+ channel in murine gastrointestinal smooth musclesAm J Physiol Gastrointest Liver Physiol20092971G107G11519389803
   PubMed Web of Science ®Google Scholar
• FerronGMPaulJFruncilloRMultiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteersJ Clin Pharmacol200242217518211831540
   PubMed Web of Science ®Google Scholar
• McNeillyRJTorchinCDAndersonLWKapetanovicIMKupferbergHJStrongJMIn vitro glucuronidation of D-23129, a novel anticonvulsant, by human liver microsomes and liver slicesXenobiotica19972754314419179986
   PubMed Web of Science ®Google Scholar
• BorlakJGasparicALocherMSchupkeHHermannRN-Glucuronidation of the antiepileptic drug retigabine: results from studies with human volunteers, heterologously expressed human UGTs, human liver, kidney, and liver microsomal membranes of Crigler-Najjar type IIMetabolism20065671172116713428
   PubMed Web of Science ®Google Scholar
• HermannRFerronGMErbKEffects of age and sex on the disposition of retigabineClin Pharmacol Ther2003731617012545144
   PubMed Web of Science ®Google Scholar
• HempelRSchupkeHMcNeillyPJMetabolism of retigabine (D-23129), a novel anticonvulsantDrug Metab Dispos199927561362210220491
   PubMed Web of Science ®Google Scholar
• FerronGMPaulJRichardsLGetsyJTroySRetigabine does not alter the pharmacokinetics of a low dose oral contraceptive in womenNeurology200156Suppl 3A335A336
   Google Scholar
• HermannRKnebelNGNiebchGRichardsLBorlakJLocherMPharmacokinetic interaction between retigabine and lamotrigine in healthy subjectsEur J Clin Pharmacol2003581279580212698305
   PubMed Web of Science ®Google Scholar
• FerronGMPatatAParksVRolanPTroySMLack of pharmacokinetic interaction between retigabine and phenobarbitone at steady-state in healthy subjectsBr J Clin Pharmacol2003561394512848774
   PubMed Web of Science ®Google Scholar
• BialerMJohannessenSILevyRHPeruccaETomsonTWhiteHSProgress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX)Epilepsy Res200983114319008076
   PubMed Web of Science ®Google Scholar
• PorterRJPartiotASachdeoRNohriaVAlvesWMRandomized, multicenter, dose-ranging trial of retigabine for partial-onset seizuresNeurology200768151197120417420403
   PubMed Web of Science ®Google Scholar
• FrenchJAAbou-KhalilBWLeroyRFRESTORE 1/Study 301 InvestigatorsRandomized double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsyNeurology201176181555156321451152
   PubMed Web of Science ®Google Scholar
• BrodieMJLercheHGil-NagelARESTORE 2 Study GroupEfficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsyNeurology201075201817182420944074
   PubMed Web of Science ®Google Scholar
• PorterRJBurdetteDEGil-NagelARetigabine as adjunctive therapy in adults with partial-onset seizures: integrated analysis of three pivotal controlled trialsEpilepsy Res Epub April 16, 2012
   Web of Science ®Google Scholar
• BrickelNGandhiPVanlandinghamKHammondJDerossettSThe urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ (K(v) 7) potassium channelsEpilepsia201253460661222428574
   PubMed Web of Science ®Google Scholar
• IpavecaVMartireaMBarresebVTaglialatelaMCurròDKV7 channels regulate muscle tone and nonadrenergic noncholinergic relaxation of the rat gastric fundusPharmacol Res201164439740921740972
   PubMed Web of Science ®Google Scholar
• StrengTChristophTAnderssonKEUrodynamic effects of the K+ channel (KCNQ) opener retigabine in freely moving, conscious ratsJ Urol20041725 Pt 12054205815540788
   PubMed Web of Science ®Google Scholar
• RodeFSvaløJSheykhzadeMChristianLRønnLCFunctional effects of the KCNQ modulators retigabine and XE991 in the rat urinary bladderEur J Pharmacol20106381–312112720385123
   PubMed Web of Science ®Google Scholar
• ShillitoPMolenaarPCVincentAAcquired neuromyotonia: evidence for autoantibodies directed against K+ channels of peripheral nervesAnn Neurol19953857147227486862
   PubMed Web of Science ®Google Scholar
• Blackburn-MunroGJensenBSThe anticonvulsant retigabine attenuates nociceptive behaviors in rat models of persistent and neuropathic painEur J Pharmacol20034602–310911612559370
   PubMed Web of Science ®Google Scholar
• MunroGErichsenHKMirzaNRPharmacological comparison of anticonvulsant drugs in animal models of persistent pain and anxietyNeuropharmacology200753560961817714743
   PubMed Web of Science ®Google Scholar
• HansenHHAndreasenJTWeikopPMirzaMScheel-KrügerJMikkelsenJDThe neuronal KCNQ channel opener retigabine inhibits locomotor activity and reduces forebrain excitatory responses to the psychostimulants cocaine, methylphenidate and phencyclidineEur J Pharmacol20075701–3778817628530
   PubMed Web of Science ®Google Scholar
• RichterASanderSERundfeltCAntidystonic effects of Kv7 (KCNQ) channel openers in the dtsz mutant, an animal model of primary paroxysmal dystoniaBr J Pharmacol2006149674775317016514
   PubMed Web of Science ®Google Scholar
• KorsgaardMPHartzBPBrownWDAhringPKStrøbaekDMirzaNRAnxiolytic effects of Maxipost (BMS-204352) and retigabine via activation of neuronal Kv7 channelsJ Pharmacol Exp Ther2005314128229215814569
   PubMed Web of Science ®Google Scholar
• NgFLDavisAJJeppsTAExpression and function of the K+ channel KCNQ genes in human arteriesBr J Pharmacol20111621425320840535
   PubMed Web of Science ®Google Scholar
• JoshiSSedivyVHodycDHergetJGurneyAMKCNQ modulators reveal a key role for KCNQ potassium channels in regulating the tone of rat pulmonary artery smooth muscleJ Pharmacol Exp Ther2009329136837619151245
   PubMed Web of Science ®Google Scholar